Colorcon expands functional film coatings through the CR Alliance with DuPont
The Aquacoat product line provides modified release drug profiles with the added benefit of global regulatory acceptance.
DuPont Nutrition & Biosciences, a business unit of DowDuPont Specialty Products Division, has agreed to enhance the current portfolio of Controlled Release (CR) Alliance products distributed by Colorcon by adding the Aquacoat range of modified release products.
The Aquacoat product line includes Aquacoat ECD for sustained release and Aquacoat CPD for enteric coating applications. These aqueous functional coatings are designed for use in both pharmaceutical and nutritional solid dose applications. They provide modified release drug profiles with the added benefit of global regulatory acceptance.
Jayesh Parmar, General Manager at Colorcon says: “The addition of these products further augments the Alliance’s ability to fulfill the needs of the pharmaceutical industry and provide unique solutions to deliver efficiency, cost savings, and dependable performance.”
Martti Hedman, CEO adds: “Colorcon and DuPont, together through the Alliance, continue to deliver increased value and innovative solutions for our pharmaceutical customers. The addition of new products strengthens the global relationship and enhances our market leadership position.”
“We want to ensure that our customers receive the highest possible levels of service,” adds Pauel Fokin, Global Commercial Director, Pharma Solutions, DuPont. “This move provides a one-stop shop for their controlled release application needs and demonstrates our continued commitment to the Controlled Release Alliance with Colorcon.”
Since 2007, the Alliance has served the needs of the pharmaceutical industry, providing customized solutions, products and support services for pharmaceutical product development. The addition of the Aquacoat products into the Alliance portfolio demonstrates the continued strong relationship between Colorcon and DuPont and enhances the range of solutions provided to meet industry needs.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance